Synergy Pharmaceuticals (SGYP) Stock Soars after Positive Results for Plecanatide

Shares of Synergy Pharmaceuticals Inc. (SGYP) were trading up +1.74 or +21.19 percent to $9.95 per share in Thursday's premarket after the company announced positive results in the second Phase 3 trial of its gastrointestinal drug plecanatide in patients suffering from Chronic Idiopathic Constipation or CIC. Synergy Pharmaceutical stock closed at $8.21 per share, down -0.03 or -0.39 percent in Wednesday's regular trading session.


New York, New York based Synergy Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development of new therapies to treat gastrointestinal disease and disorders based on uroguanylin, a natural human hormone.
The hormone is naturally produced in the small intestine and plays an important role in regulating the normal function of the digestive tract through its activity on the guanylate cyclase-C or GC-C receptor. Synergy has developed two analogs of uroguanylin, dolcanatide (SP-333) and plecnatide.

Synergy reported this morning that it had obtained positive results in the second of two pivotal Phase 3 clinical trials to evaluate the safety and efficacy of plecanatide in two different treatment doses: 3.0 mg and 6.0 mg. The studies were conducted on 1,337 adult patients (21.6 percent males and 78.4 percent females) suffering from chronic idiopathic constipation or CIC, which were given a tablet once a day.

Analysis of the preliminary data indicated that both the 3.0 mg and 6.0 mg doses of plecanatide met the primary endpoint of the study. The study demonstrated a significant statistical difference in the proportion of patients in the intention to treat population that were durable overall responders compared to patients given a placebo.

Gary S. Jacob, Ph.D., Chairman and Chief Executive Officer of Synergy said in a press release that, "We are thrilled with the positive results of this trial, we now have successfully completed the two largest phase 3 trials ever conducted in CIC and plecanatide's treatment effect and tolerability profile have been remarkably consistent. We look forward to filing our first NDA with plecanatide in the CIC indication and the opportunity to bring this novel treatment to market.

The first phase 3 CIC trial, which also obtained positive results was conducted in North America on 1,346 adult patients randomly assigned to take 3.0 mg, 6.0 mg or a placebo once a day for a 12-week period. The primary endpoint required for approval in the United States was met by both studies.

The results of the most recent 12-week studies showed a positive response in 20.1 percent of patients taking the 3.0 mg dose and 20.0 percent for the group given a 6.0 mg dose compared to 12.8 percent for the placebo group in both doses. The durable overall responder endpoint met current FDA endpoint requirements for approval in the United States for the treatment of CIC.

Synergy Pharmaceutical stock has almost tripled since trading under $3.50 per share in mid-May. The stock has sold off somewhat this morning and will open somewhere near its yearly high of $9.76.

Other News About SGYP

Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer

Hamilton has 19 years experience in the pharmaceutical industry having previously worked for Shire Pharmaceutical's GI unit.

3 Biotech Stocks That Could Soon Rocket Higher

Synergy Pharmaceuticals is included in this Motley Fool article on biotech stocks.

Other Stocks in the News

Amazon Prime signs ex-Top Gear crew for new car show

The UK's television show crew has been signed by Amazon Prime to start a new automotive series.

Facebook profit falls 9 percent as costs soar

Company predicts expenses will increase 55 to 60 percent in 2015 from last year.

Published on Jul 30, 2015
By Jay Hawk
Jay Hawk
Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.

Copyrighted 2016. Content published with author's permission.

Posted in ...